1. Clinical Overview of Hexarelin
Molecule: Hexarelin (Examorelin) is a synthetic growth hormone-releasing peptide (GHRP) that potently stimulates endogenous GH secretion via ghrelin receptor (GHS-R1a) agonism.
Classification: Growth Hormone Secretagogue (GHS) · Synthetic hexapeptide · Ghrelin receptor (GHS-R1a) agonist · Anabolic and cardioprotective peptide
Clinical Significance
- Potent GH-releasing effects, stronger than GHRP-2 and GHRP-6
- Indirect increase in IGF-1 production
- Anti-catabolic, pro-anabolic effects on lean mass
- Cardioprotective potential in preclinical and early human data
2. Mechanisms of Action
2.1 Pituitary GH Release
- Strong binding to GHS-R1a in anterior pituitary
- Amplifies endogenous pulsatile GH secretion
- Stimulates hepatic IGF-1 synthesis
2.2 Ghrelin-Mimetic Effects
- Promotes appetite and nutrient partitioning
- Enhances mitochondrial metabolism
- Supports muscle regeneration and recovery
2.3 Cardiac Receptor Activation
- GHS-R1a receptors in myocardium
- Improves left ventricular function in heart failure models
- Reduces myocardial fibrosis and apoptosis
2.4 Anabolic & Anti-Catabolic Activity
- Increases lean body mass
- Decreases visceral adiposity
- May protect against glucocorticoid-induced catabolism
3. Evidence Summary — Clinical Domains
3.1 Anabolic Support & Muscle Wasting
Promotes GH/IGF-1 axis activation, muscle hypertrophy, and improved nitrogen retention. Investigated for cachexia, sarcopenia, and age-related muscle loss.
3.2 Performance & Recovery
Enhanced muscle repair post-exercise, reduces exercise-induced breakdown, may improve strength and endurance via GH/IGF-1.
3.3 Cardiac Function & Heart Failure Models
Improves LVEF, reduces fibrosis in heart failure models. Human pilot trials show improved cardiac biomarkers.
3.4 Fat Loss & Metabolic Shift
Mild lipolytic effects via GH pathway. May improve insulin sensitivity over time. Reduction in visceral adiposity noted in some trials.
4. Clinical Protocols
4.1 Administration Route
Subcutaneous injection preferred (1–2× daily). IM optional.
4.2 Reconstitution
2 mg lyophilized vial · Reconstitute with 2 mL bacteriostatic saline · Final concentration: 1 mg/mL
4.3 Dosing Protocols
Standard Regenerative: 100 mcg × 2/day (AM and PM) · 8–12 weeks
Performance/Anabolic: 200 mcg × 2/day (fasted AM and pre-bed) · 6–10 weeks
Cardiac Support (Research): 100 mcg daily × 10–12 weeks · Evaluate LV function, BNP, troponins
Anti-Catabolic: 100–200 mcg once daily in chronic illness or corticosteroid use
5. Clinical Integration Strategies
5.1 Hexarelin + CJC-1295 (No DAC)
Synergistic GH-releasing stack. Pulsatile GH + GHRH enhancement.
5.2 Hexarelin + BPC-157 or TB-500
Musculoskeletal recovery synergy. Supports tendon, ligament, and muscle regeneration.
5.3 Hexarelin + MOTS-c or SS-31
Mitochondrial health during anabolic phase. Offsets fatigue, supports cardiovascular tissue.
5.4 Hexarelin + 5-Amino-1MQ
Metabolic recomposition synergy. Lean mass gain + NNMT modulation.
6. Decision Tree for Clinical Research Use
Primary Goal
| Goal | Hexarelin Use |
|---|
| Muscle gain | Yes, moderate-high dose |
| Cardiac remodeling | Consider, low dose |
| GH stimulation (pulsatile) | Ideal candidate |
| Anti-catabolic support | Strong consideration |
| Pediatric GH deficiency | Not recommended (use GH therapy) |
Contraindication or Caution Needed
| Condition | Consideration |
|---|
| Active malignancy | Use caution (GH/IGF-1 axis) |
| Diabetes | Monitor glucose (transient insulin resistance) |
| Pregnancy | Contraindicated |
7. Safety, Side Effects & Monitoring
7.1 Side Effects (Generally Mild)
- Hunger
- Injection site irritation
- Water retention (mild)
- Transient prolactin increase
- Numbness/tingling (rare)
7.2 Contraindications
- Active malignancy
- Pregnancy/lactation
- Uncontrolled diabetes or retinopathy
7.3 Monitoring
- IGF-1 levels (baseline and 6–8 weeks)
- Fasting glucose (optional)
- Prolactin (if symptomatic)
- Cardiac markers if used in CHF context
Legal Disclaimer
The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.
Hexarelin, and other peptides referenced herein are not FDA-approved drugs. Their clinical use may constitute off-label or investigational use.
Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented.
By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.
Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.
References — Hexarelin Clinical Reference Guide
1. Garcia, J. M., et al. (1997). Effects of hexarelin on growth hormone secretion and body composition. Journal of Clinical Endocrinology & Metabolism, 82(2), 296–301.
2. Smith, R. G., et al. (2000). Ghrelin and growth hormone secretagogues: a new era of endocrine regulation. Trends in Endocrinology & Metabolism, 11(3), 118–123.
3. Locatelli, V., et al. (2002). Hexarelin protects the heart against ischemia/reperfusion injury through growth hormone-independent mechanisms. Endocrinology, 143(12), 4681–4689.
4. Rossoni, G., et al. (2009). Hexarelin-induced cardioprotection: role of nitric oxide and PI3K/Akt signaling. Cardiovascular Research, 83(2), 303–312.
5. Nass, R., et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Annals of Internal Medicine, 149(9), 601–608.
6. Nagaya, N., et al. (2004). Ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in patients with chronic heart failure. Circulation, 110(24), 3674–3679.